We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMRA icon
226
Neumora Therapeutics
NMRA
$304M
– –
-26,108
Closed -$26.1K
NVS icon
227
PUT
Novartis
NVS
$296B
– –
-50,000
Closed -$5.57M
PHAT icon
228
CALL
Phathom Pharmaceuticals
PHAT
$676M
– –
-10,100
Closed -$63.3K
PTCT icon
229
PTC Therapeutics
PTCT
$5.99B
– –
-50,023
Closed -$2.55M
RLYB icon
230
Rallybio
RLYB
$87.6M
– –
-1,675
Closed -$8.77K
SLDB icon
231
Solid Biosciences
SLDB
$837M
– –
-34,479
Closed -$128K
SLNO
232
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-50,000
Closed -$3.57M
SWTX
233
CALL
DELISTED
SpringWorks Therapeutics
SWTX
– –
-15,000
Closed -$662K
TIL icon
234
Instil Bio
TIL
$49.3M
– –
-24,328
Closed -$422K
TNGX icon
235
Tango Therapeutics
TNGX
$4.43B
– –
-41,346
Closed -$56.6K
YARW
236
Yarrow Bioscience, Inc. Common Stock
YARW
$113M
– –
-1,408
Closed -$111K
XLO icon
237
Xilio Therapeutics
XLO
$60.6M
– –
-2,857
Closed -$29K
ZYME icon
238
Zymeworks
ZYME
$1.75B
– –
-50,000
Closed -$596K
UCFIW
239
CN Healthy Food Tech Group Warrant
UCFIW
– –
-25,000
Closed -$800
JVSA
240
DELISTED
JV SPAC Acquisition Corp
JVSA
– –
-30,000
Closed -$322K
ADGM
241
Adagio Medical Holdings
ADGM
$15.5M
– –
-76,757
Closed -$61.8K
UPB
242
Upstream Bio Inc
UPB
$384M
– –
-15,000
Closed -$91.8K
SPRB
243
Spruce Biosciences
SPRB
$130M
– –
-5,383
Closed -$117K
ITCI
244
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-48,044
Closed -$6.34M
KDK
245
Kodiak AI
KDK
$836M
– –
-90,466
Closed -$1.01M
6 7 8 9
10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.